View Item 

Show simple item record

Comparative Cost‐effectiveness of Alternative Empiric Antimicrobial Treatment Options for Suspected Enterococcal Bacteremia
dc.contributor.authorMcComb, Meghan N.en_US
dc.contributor.authorCollins, Curtis D.en_US
dc.date.accessioned2014-07-03T14:41:14Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-07-03T14:41:14Z
dc.date.issued2014-06en_US
dc.identifier.citationMcComb, Meghan N.; Collins, Curtis D. (2014). "Comparative Cost‐effectiveness of Alternative Empiric Antimicrobial Treatment Options for Suspected Enterococcal Bacteremia." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34(6): 537-544.en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107482
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherPharmacoeconomicsen_US
dc.subject.otherEnterococcal Bacteremiaen_US
dc.subject.otherDaptomycinen_US
dc.subject.otherLinezoliden_US
dc.subject.otherVancomycinen_US
dc.titleComparative Cost‐effectiveness of Alternative Empiric Antimicrobial Treatment Options for Suspected Enterococcal Bacteremiaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107482/1/phar1393.pdf
dc.identifier.doi10.1002/phar.1393en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceMermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter‐related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1 – 45.en_US
dc.identifier.citedreferenceBiendenback DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagn Microbiol Infect Dis 2004; 50: 59 – 69.en_US
dc.identifier.citedreferenceVergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. Ann Intern Med 2001; 135: 484 – 92.en_US
dc.identifier.citedreferenceDeshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin‐resistant enterococci from North America and Europe: a report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2007; 58: 163 – 70.en_US
dc.identifier.citedreferenceBhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case‐control study comparing risk factors, treatment, and outcomes for vancomycin‐resistant and –susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36: 145 – 58.en_US
dc.identifier.citedreferenceMoses V, Jerobin J, Nair A, et al. Enterococcal bacteremia is associated with prolonged stay in the medical intensive care unit. J Glob Infect Dis 2012; 4: 26 – 30.en_US
dc.identifier.citedreferenceLodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin‐resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34: 922 – 9.en_US
dc.identifier.citedreferenceDiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin‐resistant and vancomycin‐susceptible enterococcal bloodstream infections: a meta‐analysis. Clin Infect Dis 2005; 41: 327 – 33.en_US
dc.identifier.citedreferenceButler AM, Olsen MA, Merz LR, et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol 2010; 31: 28 – 35.en_US
dc.identifier.citedreferenceSuppli M, Aabenhus R, Harboe ZB, Andersen LP, Tvede M, Jensen JUS. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect 2011; 17: 1078 – 83.en_US
dc.identifier.citedreferenceForrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital‐acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 2008; 52: 3558 – 63.en_US
dc.identifier.citedreferenceRed Book Online; Micromedex 2.0. Thomson Reuters 1974–2012. Available from: http://www.thomsonhc.com /micromedex2.com. Accessed June 18, 2013.en_US
dc.identifier.citedreferenceBureau of Labor Statistics. Consumer price index. Available from http://www.bls.gov/. Accessed June 12, 2013.en_US
dc.identifier.citedreferenceFowler RA, Hill‐Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM. Cost‐effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003; 18: 181 – 91.en_US
dc.identifier.citedreferenceWorld Health Organization. Global health observatory data repository life tables. Available from http://apps.who.int/ghodata/. Accessed June 12, 2013.en_US
dc.identifier.citedreferenceMcNeil SA, Malani PN, Chenoweth CE, et al. Vancomycin‐resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006; 42: 195 – 203.en_US
dc.identifier.citedreferenceZaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin‐resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin‐resistant enterococci. Clin Infect Dis 2002; 35: 1139 – 46.en_US
dc.identifier.citedreferenceWeinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin‐resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007; 13: 615 – 21.en_US
dc.identifier.citedreferenceArias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE. Unmet needs and prospects for ortivancin in the management of vancomycin‐resistant enterococcal infections. Clin Infect Dis 2012; 54 ( S3 ): S233 – 8.en_US
dc.identifier.citedreferenceSader HS, Jones RN. Antimicrobial susceptibility of Gram‐positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008). Diagn Microbiol Infect Dis 2009; 65: 158 – 62.en_US
dc.identifier.citedreferenceHidron AI, Edwards JR, Patel J, et al. Antimicrobial‐resistant pathogens associated with healthcare‐associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008; 29: 996 – 1011.en_US
dc.identifier.citedreferenceDiekema DJ, Pfaller MA, Jones RN, The SENTRY Participants Group. Age‐related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America SENTRY Antimicrobial Surveillance Program, 1997–2000. Int J Antimicrob Agents 2002; 20: 412 – 18.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar1393.pdf
Size:
249.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.